FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C. Vivaldi
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors C. Vivaldi1, E. Vasile1, C. Caparello1, V. Perrone1, F. Caniglia1, N. De Lio1, C. Croce1, L. Fornaro2, G. Musettini1, G. Pasquini3, I. Pecora1, M. Lencioni1, C. Cappelli1, D. Caramella1, A. Falcone1, U. Boggi1
  • 1Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, /
  • 2U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, /
  • 3Department of Oncology, University Hospital, Pisa, Italy, /


Chemotherapy and chemoradiation are the main options in LAPC while surgery becomes feasible only in a small proportion of patients after neoadjuvant therapy. FOLFIRINOX is an active treatment in advanced pancreatic cancer. FOLFOXIRI is a similar regimen, with lower dose of irinotecan and no 5-fluorouracil bolus, that has shown good activity in advanced colorectal cancer. We prospectively evaluated the activity of FOLFOXIRI in LAPC.